GlaxoSmithKline's recent agreement to pay $750 million to resolve civil and criminal liability in connection with alleged cGMP failures at its now-shuttered facility in Cidra, Puerto Rico, is outside the norm and some believe opens up a new frontier for US whistleblower suits.
It is undoubtedly sending "shock waves" throughout the industry and means that any FDA-regulated firm "must pay close attention to...